Cotinga Pharmaceuticals Valeur / Action
Quel est le Valeur / Action de Cotinga Pharmaceuticals?
Le Valeur / Action de Cotinga Pharmaceuticals, Inc. est -0.18
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur TSXV par rapport à Cotinga Pharmaceuticals
Que fait Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Entreprises avec valeur / action similaire à Cotinga Pharmaceuticals
- Alpha MOS SA a Valeur / Action de -0.18
- China Bozza Development a Valeur / Action de -0.18
- ImaginOn a Valeur / Action de -0.18
- Canxgold Mining Corp a Valeur / Action de -0.18
- Smart Employee Benefits a Valeur / Action de -0.18
- Aton Resources a Valeur / Action de -0.18
- Cotinga Pharmaceuticals a Valeur / Action de -0.18
- Pixium Vision SA a Valeur / Action de -0.18
- Atlantic Avenue Acquisition Corp a Valeur / Action de -0.18
- Navya SA a Valeur / Action de -0.18
- LightJump Acquisition a Valeur / Action de -0.18
- MedMen Enterprises a Valeur / Action de -0.18
- Global Bio-chem Technology a Valeur / Action de -0.17